Skip to content

Whole Blood Specimen Collection From Pregnant Subjects

Whole Blood Specimen Collection From Pregnant Subjects

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02430584
Enrollment
5000
Registered
2015-04-30
Start date
2015-03-31
Completion date
2021-05-31
Last updated
2020-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

DiGeorge Syndrome, Down Syndrome, Edwards Syndrome, Klinefelter Syndrome, Patau Syndrome, Perinatal Infections, Turner Syndrome

Brief summary

To obtain whole blood specimens from pregnant subjects to be used for research and development and clinical validation studies of prenatal assays.

Detailed description

This sample collection protocol allows for the identification, recruitment, and participation in women who are pregnant and are known to: 1. be at an increased risk for fetal genetic abnormalities 2. be at increased risk for congenital fetal infection by virtue of being positive by initial screening tests, or are known to have an active infection during this pregnancy. 3. possess irregular blood group antigens (the subject or the father of the baby) and are therefore at increased risk for fetal sensitization during this pregnancy.

Interventions

Sponsors

Progenity, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
FAMILY_BASED
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Subject willing to provide consent to have up to 50 mL of whole blood collected at one or more monthly (≥25 days) clinic visits * Subject is pregnant carrying a singleton fetus of 10 to 26 weeks gestational age inclusive * Subject is 18 years of age or older * Subject is at an increased risk for one or more of the following: * fetal gene and chromosome abnormalities * congenital fetal infection * known to possess irregular blood group antigens (subject or father of the baby) * known to have some other condition amenable to noninvasive prenatal testing

Exclusion criteria

* Pregnancy is non-viable

Design outcomes

Primary

MeasureTime frame
Whole blood collectionOne or more monthly clinic visits (≥25 days apart) over 13 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026